initial public offerings (IPOs) trading on American exchanges

Tuesday, March 30, 2021

Sigilon Therapeutics (SGTX) began trading on the Nasdaq on Fri 4 Dec 20

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. 
  • Sector(s): Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 62
  • Incorporated in 2015 
  • Headquartered in Cambridge, Massachusetts

No comments:

Post a Comment